

# EPILEPSY THERAPIES AND DIAGNOSTICS DEVELOPMENT XVII

---

*May 31-June 2, 2023*  
*JW Marriott Miami Turnberry*  
*Aventura, Florida*

## Wednesday, May 31

**7:00-8:00**     **Breakfast and Registration**

**8:00-8:25**     **Introduction and Welcome from the AES, EF and ILAE**  
*Jacqueline French, MD, President, Epilepsy Study Consortium, Inc.*  
*Manisha Patel, PhD, President, AES*  
*Brandy Fureman, PhD, Chief Outcomes Officer, EF*  
*Helen Cross, MD, PhD, President, ILAE*

### **SESSION I: EPILEPSY RESEARCH ROUNDTABLE UPDATE: 2022/2023**

#### **Ia: ANTI-EPILEPTOGENESIS and DISEASE MODIFICATION**

**Moderator:**   **Jacqueline French, MD**

**8:25-8:30**     **Patient/Caregiver Perspective**  
*Traci Abeyta*

**8:30-8:50**     **Disease Modification and Antiepileptogenesis: Community, Industry and Regulatory Definitions**  
*Konrad Werhahn, MD, PhD*

**8:50-9:10**     **Disease Modification Trial Designs: Measuring the Things That Matter**  
*Nathan Fountain, MD*

**9:10-9:30**     **Can we Prevent Epilepsy: The Promise of the PREVENT Trial and Beyond**  
*Martina Bebin, MD*

**9:30-9:50**     **From Success to Success: What can be Learned from Acquired/TSC Epilepsy Trials That Can Inform Prevention/PTE Trials?**  
*Pavel Klein, MD*

**9:50-10:10**   **Discussion**

**10:10-10:30**   **Break**

## **Ib: BIOMARKERS**

**Moderator:** Caitlin Grzeskowiak, PhD

**10:30-10:35 Patient/Caregiver Perspective**

*JayEtta Hecker, MS*

**10:35-10:55 What Biomarkers are Most Promising for Epilepsy Development?**

*Sudha Kessler, MD, MSCE*

**10:55-11:15 Can We Use Biomarkers (EEG, other) as Outcome Measures and to Optimize Patient Recruitment into Trials?**

*Jay Pathmanathan, MD, PhD*

**11:15-11:35 Discussion**

## **SESSION II: PRECLINICAL**

**Moderator:** Marc Dichter, MD, PhD

**11:35-11:40 Patient/Caregiver Perspective**

*Veronica Hood, PhD*

**11:40-12:00 Seizures in Animal Models During Safety Studies: Do They Predict Seizure Worsening in Humans?**

*Steve White, PhD, and Michelle Guignet, PhD*

**12:00-1:15 Lunch (Not included in registration)**

## **SESSION II: PRECLINICAL (CONTINUED)**

**1:15-1:35 From Science Fiction to Science-What Pre-Clinical Concepts Will be the Next to Make it to the Clinic?**

*Manisha Patel, PhD*

**1:35-1:55 Update on the Anticonvulsant Drug Development (ADD) Program**

*Cameron Metcalf, PhD*

**1:55-2:15 Discussion**

## **SESSION III: CLINICAL TRIAL DESIGN ISSUES**

**Moderator:** Kamil Detyniecki, MD

**2:15-2:20 Patient/Caregiver Perspective**

*Heather Longo*

**2:20-2:40 Time to Event Designs**

*Wesley Kerr, MD, PhD*

- 2:40-3:00**     **Panel: Where Have all the Patients Gone?  
Difficult Recruitment into Focal Epilepsy Studies and What We Can do About it**  
*Daniel Friedman, MD, and Michael Sperling, MD*
- 3:00-3:20**     **Break**
- 3:20-3:40**     **Debate: Open Label Extension After Double Blind-Nice to Have or Must Have**  
*Michael Sperling, MD vs Jacqueline French, MD*
- 3:40-4:00**     **Design of Long-term Outcome Measures for Disease Modifying Therapies to  
Assess Co-morbidities**  
*JayEtta Hecker, MS and Natasha Ludwig, PhD*
- 4:00-4:20**     **Clinical Endpoint for Hard to Identify and Count Seizures (e.g., Absence,  
Myoclonus)**  
*Dennis Dlugos, MD*
- 4:20-4:40**     **Discussion**
- 4:40-5:10**     **Panel: The Impact of CROs on Clinical Trials in 2023**  
*Nathan Fountain, MD, David Vossler, MD, Sudha Kessler, MD, MSCE,  
Lilly Frohlich, MPH, and Jennie Minnick*
- 5:10-5:30**     **Discussion**

## **Thursday, June 1**

- 7:00-8:00**     **Breakfast and Registration**

### **SESSION IV: BEYOND SEIZURES**

**Moderator:** **Andres Kanner, MD**

- 8:00-8:05**     **Patient/Caregiver Perspective**  
*Skylar Economy*
- 8:05-8:25**     **Cardiovascular Risk in Epilepsy: Are our ASMs the Cause or the Prevention?**  
*Colin Josephson, MD*
- 8:25-8:45**     **Can We Treat Co-morbidities? Treatments for Memory and Cognition Issues in  
People with Epilepsy**  
*Kimford Meador, MD*
- 8:45-9:05**     **Selection and Validation of Non-Seizure Endpoints in Epilepsy Clinical Trials**  
*Kimberly Parkerson, MD, PhD*
- 9:05-9:25**     **Discussion**

## **SESSION V: DEVICES**

**Moderator: Brandy Fureman, PhD**

**9:25-9:30 Patient/Caregiver Perspective**  
*Ryan DeLoughry*

**9:30-9:50 Use of Seizure Detection Devices as Endpoints in Clinical Trials-Ready for Prime Time?**  
*Daniel Friedman, MD*

**9:50-10:10 Break**

**10:10-10:30 Trials and Tribulations of Electronic Seizure Diaries**  
*Gail Farfel, PhD*

**10:30-10:50 Optimizing Stimulation Devices: Are we Making any Progress?**  
*Michael Sperling, MD*

**10:50-11:10 Discussion**

## **SESSION VI: RARE EPILEPSIES**

**Moderator: Kelly Knupp, MD**

**11:10-11:15 Patient/Caregiver Perspective**  
*Tracy Dixon-Salazar, PhD*

**11:15 -11:35 When Does a Gene Become a Disease: ICD-10 Codes for Genetic Epilepsies: How to get Them and Why do we Need Them?**  
*David Vossler, MD*

**11:35-11:55 ASOs and Gene Therapies: What are the Risk Tradeoffs and How Far Will Families be Willing to go?**  
*Gregory Krauss, MD*

**11:55-12:15 Discussion**

**12:15-1:45 Lunch (Not included in registration)**

## **1:45-5:00 SHARK TANK COMPETITION**

**1:45-1:50 Shark Tank Welcome**  
*Caitlin Grzeskowiak, PhD*

**1:50-2:00 Epival: For Epilepsy Families Update**  
*Amir Helmy, CEO, Epival*

**2:00-2:10**     **An Update on Neuraura's Electrodes to Improve Brain Mapping**  
Pierre Wijdenes, MEng, PhD, CPO & Co-founder, Neuraura

**Moderator: Jacqueline French, MD**

**Sharks:**

**Carter Caldwell, MBA, Penn Medicine Co-Investment Program**

**Elizabeth Corbett, Board of Directors, Epilepsy Foundation**

**Sudha Kessler, MD, MSCE, Children's Hospital of Philadelphia**

**Lidia Moura, MD, PhD, MPH, Harvard Medical School**

**Mark Theeuwes, CEO, Receptor Life Science**

**Shark Tank Finalists:**

**All Hands Life Signature Mat: Safer Spaces for a More Joyful Life**  
Shana Bairrington, Founder Allhands Life

**EnCompass: A Personalized Companion for Precision Epilepsy Surgery**  
Nitin Tandon, MD, FAANS, BrainDynamics, Inc.

**Clinical Decision Support Platform for Epilepsy Surgical Planning**  
Noam Peled, CEO and Co-founder, FIND Neuro

**Modernize Childhood Absence Epilepsy Care with a Time-Tested Tool**  
Rachel Kuperman, MD, Eysz

**EASEE® - Stimulating the Brain, Reducing Epileptic Seizures**  
Angela Liedler, MD, CEO, Precisis GmbH

**Easy Brain Diagnostics**  
Paul Loomis, CCO, BrainCapture

**6:00 DINNER RECEPTION**

**2023 EPILEPSY FOUNDATION LIFETIME ACCELERATOR AWARD**

**RECIPIENT: JACQUELINE A. FRENCH, MD**

## Friday, June 2

**7:00-8:00**      **Breakfast and Registration**

**8:00-8:20**      **Epilepsy Study Consortium, Inc.**  
*Jacqueline French, MD*

**8:20-8:40**      **Update on NINDS Funding for Therapy and Device Development in Epilepsy**  
*Brian Klein, PhD and Brooks Gross, PhD*

**8:40-8:50**      **Discussion**

### **SESSION VII: DRUG PIPELINE—PRE-CLINICAL**

**Moderator:**    **Roger Porter, MD**

**8:50- 9:00**      **Preclinical Data Supporting the Efficacy of OV329, A Next Generation GABA Aminotransferase Inhibitor, Against Seizures**  
*Julia Tsai, PhD, Ovid Therapeutics*

**9:00-9:10**      **Discovery and Characterisation of ETX-123: a Novel Kv7.2/3 Opener**  
*Manuela Cerina, PhD, Eliem Therapeutics*

**9:10-9:20**      **Disease Modifying RNA Therapy for Treatment of Epilepsy**  
*Stine N. Hansen, PhD, NEUmiRNA Therapeutics*

**9:20-9:30**      **From Oil to Tablet: The New Platform of Cannabidiol Medicine**  
*Abdel-Rahman Lawendy, MD, PhD, London Research & Pharmaceuticals*

**9:30-9:40**      **PrevEp Update: Network Pharmacology to Prevent Acquired Epilepsy, and New Portfolio Developments**  
*Pavel Klein, MD, PrevEp Inc.*

**9:40-9:50**      **CUE® Platform by SynapCell: an EEG-Based Preclinical Platform Dedicated to ASMs, from Small Molecules to Gene Therapies**  
*Corinne Roucard, PhD, SynapCell SAS*

**9:50-10:00**      **AMT-260, a Novel AAV9-MicroRNA Based Therapy for the Treatment of Refractory Temporal Lobe Epilepsy**  
*Andreas Borta, uniQure*

**10:00-10:10**      **Next Gen AAV Therapeutics for Treatment of Genetic Epilepsy Caused by Mutations in the STXBP1 Gene**  
*Nicholas Flytzanis, PhD, Capsida Biotherapeutics*

## **SESSION VIII : DRUG AND DRUG DEVICE PIPELINE—CLINICAL**

**Moderator: Daniel Friedman, MD**

**10:10-10:20 Importance of Intracerebroventricular ROA: Route of Access**

*Daniel Abrams, MD, Cerebral Therapeutics*

**10:20-10:30 A Phase I/II Clinical Trial of NRTX-1001: Human Stem Cell-Derived Inhibitory Neurons for Chronic Focal Epilepsy**

*Cory Nicholas, PhD, Neurona Therapeutics*

**10:30-10:40 Soticlestat (TAK-935) Development for Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome**

*Mahnaz Asgharnejad, PharmD, Takeda Pharmaceuticals*

**10:40-11:00 Break**

**11:00-11:10 XEN1101, a Potent, Differentiated KV7 Potassium Channel Opener in Development for the Treatment Epilepsy**

*Christopher Kenney, MD, Xenon Therapeutics*

**11:10-11:20 Radiprodil a Candidate Drug in Early-Stage Clinical Development for GRIN Related Disorders**

*Michael Panzara, MD, GRIN Therapeutics*

**11:20-11:30 Update on the Clinical Development of LP352, a 5HT2C Superagonist for the Treatment of Seizures in Developmental and Epileptic Encephalopathies**

*Randall Kaye, MD, Longboard Pharmaceuticals*

**11:30-11:40 A Novel Antibody-Enzyme Fusion (VAL-1221; FAB-GAA) Clinical Candidate for Clearing Aggregated Polyglucosan Buildup and Treating Lafora Epilepsy**

*Dustin Armstrong, PhD, Parasail LLC*

**11:40-11:50 BHV-7000: A Novel Clinical-Stage Kv7.2/7.3 Activator for the Treatment of Epilepsy**

*Jason Lerner, MD, Biohaven Pharmaceuticals*

**11:50-12:00 NBI-921352: A Selective NaV1.6 Inhibitor for the Treatment of Focal Onset Seizures**

*Svetlana Shore, PhD, Neurocrine Biosciences, Inc.*

**12:00-12:10 Basimglurant- A Novel Approach in Treatment of Seizures in TSC?**

*Renata Lazarova, MD, Noema Pharma*

**12:10-1:25 Lunch (Not included in registration)**

**1:25-1:40 UCB Development Updates**

*Brian Moseley, MD, UCB*

**1:40-1:50**      **SPN-817 in Treatment-Resistant Focal Epilepsy – Clinical Program Update**  
*Welton O’Neal Jr., PharmD, Supernus Pharmaceuticals*

**1:50-2:00**      **Ganaxolone Development Update**  
*Joseph Hulihan, MD, Marinus Pharmaceuticals, Inc.*

**2:00-2:10**      **BL-001, a First-in-Class LBP Being Developed for Rare Developmental Epilepsies**  
*Paolo Baroldi, MD, PhD, Bloom Science*

## **SESSION IX: DEVICE/DIGITAL HEALTH**

**Moderator: David Squillacote, MD**

**2:10-2:20**      **Integrating Seizure Detection and Alerting Into a Remote Patient Monitoring Platform: a Novel Example from EmbracePlus**  
*Matteo Lai, Empatica Inc.*

**2:20-2:30**      **Seizure Diary: Electronic Templates Optimized for Data Capture**  
*Manuela Bossi, PhD, Signant Health*

**2:30-2:40**      **A Novel Approach to Seizure eDiary Development and Implementation**  
*Shelly Steele, WCG Clinical Endpoint Solutions*

**2:40-2:50**      **EpiCare@Home: An End-to-End Epileptic Activity and Seizure Monitoring Service for Clinical Care and Drug Development**  
*Julie Nys, PhD, Byteflies*

**2:50-3:00**      **Evolving EEG Monitoring with REMI**  
*Mark Lehmkuhle, PhD, Epitel, Inc.*

**3:00-3:10**      **Seizure Cycles: Implications for New Therapies**  
*John Hixson, MD, on behalf of Seer Medical*

**3:10-3:20**      **AWARE - Automated Awareness Testing in AE & Taking on Rare Epilepsies, 1 Seizure at a Time**  
*Tim Buckinx, Epihunter*

**3:20-3:30**      **Multichannel Transcranial Direct Current Stimulation (tDCS) for Medication-Resistant Focal Epilepsy (with Potential to Treat Depression)**  
*Alexander Rotenberg, MD, PhD, Neuroelectrics*

**3:30**              **Closing Remarks**